- Adjusted net income decreased to $40.9 million or $0.85 per share from $48.7 million or $0.94 per share in Q2 2024.
- Amphastar reported Q2 2025 net revenues of $174.4 million, a 4% decrease from $182.4 million in Q2 2024, primarily due to increased competition in legacy products.
- BAQSIMI sales grew 21% year-over-year to $46.7 million, driven by Amphastar's full global commercialization starting in 2025.
- Epinephrine sales dropped 42% to $16.2 million due to increased competition and supplier re-entry.
- Glucagon injection sales declined 25% to $20.6 million due to competition and market shift to ready-to-use products like BAQSIMI.
- Gross margins declined to 49.6% from 52.2% due to inclusion of all product costs post-transition and pricing pressures.
- Lidocaine sales increased 17% to $15 million due to higher demand from shortages of other suppliers.
- Net income decreased to $31 million or $0.64 per share from $37.9 million or $0.73 per share in Q2 2024.
- Operating expenses increased: selling, distribution and marketing by 14%, general and administrative by 5%, and R&D by 14%.
- Primatene MIST sales remained stable at $22.9 million with a 10% year-to-date growth.
Related items and other data are not available for this feed item.
Dafinchi